... Aufwind!
19.07.2006 15:00:00 (BUSINESS WIRE)
VeriChip Corporation's VeriMed(TM) Patient Identification System Selected by Horizon Blue Cross Blue Shield of New Jersey for Two-Year Pilot Program
VeriChip Corporation, a subsidiary of Applied Digital (NASDAQ: ADSX), announced today that Horizon Blue Cross Blue Shield of New Jersey, the largest health insurer in the state, has agreed to a two-year pilot program of VeriChip's VeriMed(TM) Patient Identification System in conjunction with Hackensack University Medical Center and its physicians. In this new test program, participating patients suffering from chronic diseases would be provided with the VeriChip implantable microchip, to provide emergency room staff easy access to those patients' medical information, as well as to help avoid costly or serious medical errors.
Under this trial, participating Horizon BCBSNJ members with chronic illnesses will receive VeriChip's FDA-approved, human-implantable Radio Frequency Identification (RFID) microchips inserted just under the skin of their right tricep. Each patient's unique 16-digit identifier found within the microchip will then tie into their individual electronic medical record stored within the VeriMed Patient Registry accessible by Hackensack University Medical Center's physicians. Each record will contain vital information related to the patient's condition, family contacts, lab test data, and pharmacy records helping make the difference between life and death during an emergency.
"This two-year collaboration is a milestone for VeriMed and for our implantable identification technology marking the first time a health insurer has sponsored such a program," stated Kevin McLaughlin, Chief Executive Officer, VeriChip Corporation.
For more information on VeriMed, please contact 1-800-970-CHIP or email info@verichipcorp.com. Additional information can be found online at www.verimedinfo.com.
About VeriChip Corporation
VeriChip Corporation, headquartered in Delray Beach, Florida, develops, markets and sells radio frequency identification, or RFID, systems used to identify, locate and protect people and assets. VeriChip's goal is to become the leading provider of RFID systems for people in the healthcare industry. VeriChip sells passive RFID systems for identification purposes and active RFID systems for local-area location and identification purposes. VeriChip recently began to market its VeriMed(TM) Patient Identification System which is used to rapidly and accurately identify people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, the implantable VeriChip(TM), cleared for medical use in October 2004 by the United States Food and Drug Administration.
About Applied Digital - "The Power of Identification Technology"
Applied Digital develops innovative identification and security products for consumer, commercial, and government sectors worldwide. The Company's unique and often proprietary products provide identification and security systems for people, animals, the food supply, government/military arena, and commercial assets. Included in this diversified product line are RFID applications, end-to-end food safety systems, GPS/Satellite communications, and telecomm and security infrastructure, positioning Applied Digital as the leader in identification technology. Applied Digital is the owner of a majority position in Digital Angel Corporation (AMEX:DOC).
Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and the Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.
Cu
Röckefäller
19.07.2006 15:00:00 (BUSINESS WIRE)
VeriChip Corporation's VeriMed(TM) Patient Identification System Selected by Horizon Blue Cross Blue Shield of New Jersey for Two-Year Pilot Program
VeriChip Corporation, a subsidiary of Applied Digital (NASDAQ: ADSX), announced today that Horizon Blue Cross Blue Shield of New Jersey, the largest health insurer in the state, has agreed to a two-year pilot program of VeriChip's VeriMed(TM) Patient Identification System in conjunction with Hackensack University Medical Center and its physicians. In this new test program, participating patients suffering from chronic diseases would be provided with the VeriChip implantable microchip, to provide emergency room staff easy access to those patients' medical information, as well as to help avoid costly or serious medical errors.
Under this trial, participating Horizon BCBSNJ members with chronic illnesses will receive VeriChip's FDA-approved, human-implantable Radio Frequency Identification (RFID) microchips inserted just under the skin of their right tricep. Each patient's unique 16-digit identifier found within the microchip will then tie into their individual electronic medical record stored within the VeriMed Patient Registry accessible by Hackensack University Medical Center's physicians. Each record will contain vital information related to the patient's condition, family contacts, lab test data, and pharmacy records helping make the difference between life and death during an emergency.
"This two-year collaboration is a milestone for VeriMed and for our implantable identification technology marking the first time a health insurer has sponsored such a program," stated Kevin McLaughlin, Chief Executive Officer, VeriChip Corporation.
For more information on VeriMed, please contact 1-800-970-CHIP or email info@verichipcorp.com. Additional information can be found online at www.verimedinfo.com.
About VeriChip Corporation
VeriChip Corporation, headquartered in Delray Beach, Florida, develops, markets and sells radio frequency identification, or RFID, systems used to identify, locate and protect people and assets. VeriChip's goal is to become the leading provider of RFID systems for people in the healthcare industry. VeriChip sells passive RFID systems for identification purposes and active RFID systems for local-area location and identification purposes. VeriChip recently began to market its VeriMed(TM) Patient Identification System which is used to rapidly and accurately identify people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, the implantable VeriChip(TM), cleared for medical use in October 2004 by the United States Food and Drug Administration.
About Applied Digital - "The Power of Identification Technology"
Applied Digital develops innovative identification and security products for consumer, commercial, and government sectors worldwide. The Company's unique and often proprietary products provide identification and security systems for people, animals, the food supply, government/military arena, and commercial assets. Included in this diversified product line are RFID applications, end-to-end food safety systems, GPS/Satellite communications, and telecomm and security infrastructure, positioning Applied Digital as the leader in identification technology. Applied Digital is the owner of a majority position in Digital Angel Corporation (AMEX:DOC).
Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and the Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.
Cu
Röckefäller
